Advertisement

Topics

IBI sees annual sales of $1.6-2.4 billion for Teva migraine drug

09:20 EDT 16 Sep 2018 | Globes

IBI analyst Steven Tepper has raised the target price for Teva's share from $26 to $28.

Original Article: IBI sees annual sales of $1.6-2.4 billion for Teva migraine drug

NEXT ARTICLE

More From BioPortfolio on "IBI sees annual sales of $1.6-2.4 billion for Teva migraine drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...